Citations

Showing 10 of 108152 citations.

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
Liu, Stephen V. , Duma, Narjust , Liu, Stephen V , Riaño, Ivy , Patel, Shruti

Mayo Clinic

Clinics and Practice | July 6, 2021 | Volume: 11 | Issue: 3 | Pages: 441-454

10.3390/clinpract11030059 | PMID 34287275 Get It

Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint inhibitors. Pembrolizumab, a humanized IgG4 isotype antibody, targets the programmed cell death protein 1 (PD-1) pathway to restore anti-tumor immunity. Prospective trials of pembrolizumab in patients with previously treated SCLC showed significant durability of responses. These results led to the U.S. Food and Drug Administration (FDA) granting pembrolizumab accelerated approval as second- or third-line monotherapy for patients with extensive-stage (ES) SCLC. In a recent clinical trial that included patients with previously untreated ES-SCLC, pembrolizumab in combination with platinum/etoposide met its progression-free survival endpoint, but overall survival (OS) did not cross the threshold for superiority. With the therapeutic landscape for SCLC rapidly evolving, we review prior experience and future directions of pembrolizumab in ES-SCLC.
A preliminary validation of a dynamic speech motor assessment for Swedish-speaking children with childhood apraxia of speech
Rex, Susanne , Sand, Anders , Hansson, Kristina , McAllister, Anita , Strand, Edythe, Hansson, Kristina , McAllister, Anita , Sand, Anders

Mayo Clinic

Logopedics Phoniatrics Vocology | July 6, 2021 | Volume: 47 | Issue: 4 | Pages: 230-238

10.1080/14015439.2021.1943517 | PMID 34227450 Get It

Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases
Singh, Siddharth , Heien, Herbert C., Sangaralingham, Lindsey R. , Shah, Nilay D. , Sandborn, William J. , Sangaralingham, Lindsey

Mayo Clinic

Clinical and Translational Gastroenterology | July 6, 2021 | Volume: 12 | Issue: 7 | Pages: e00380

10.14309/ctg.0000000000000380 | PMID 34228004 Get It

INTRODUCTION: Obesity has been associated with adverse disease-related outcomes and inferior treatment response to biologic agents in patients with inflammatory bowel diseases (IBDs), but its impact on the risk of treatment-related complications is unknown. We performed a cohort study examining the association between obesity and risk of serious infections in biologic-treated patients with IBD. METHODS: Using an administrative claims database, in a cohort of biologic-treated patients with IBD between 2014 and 2018 with follow-up 1 year before and after treatment initiation, we compared the risk of serious infections (infections requiring hospitalization) between obese vs nonobese patients (based on validated administrative claims) using Cox proportional hazard analysis. RESULTS: We included 5,987 biologic-treated patients with IBD (4,881 on tumor necrosis factor-α antagonists and 1,106 on vedolizumab), of whom 524 (8.8%) were classified as obese. Of the 7,115 person-year follow-up, 520 patients developed serious infection. Risk of serious infection was comparable in obese vs nonobese patients (8.8% vs 8.5%; unadjusted hazard ratio, 1.15; 95% confidence interval, 0.86–1.54). After adjusting for age, comorbidities, disease characteristics, health care utilization, use of corticosteroids, immunomodulators, and opiates, obesity was not associated with an increased risk of serious infection (adjusted hazard ratio, 0.74 [95% confidence interval, 0.55–1.01]). Similar results were seen on stratified analysis by disease phenotype (Crohn's disease and ulcerative colitis) and index biologic therapy (tumor necrosis factor-α antagonists and vedolizumab). DISCUSSION: After adjusting for comorbid conditions and disease characteristics, obesity is not independently associated with an increased risk of serious infections in biologic-treated patients with IBD.
Recurrence and mortality rates with different treatment approaches of Merkel cell carcinoma: a systematic review and meta‐analysis
Harvey, Jamison A. , Mirza, Sultan A., Erwin, Patricia J., Chan, An Wen, Brewer, Jerry D., Mirza, Sultan A., Murad, M. Hassan

Mayo Clinic

International Journal of Dermatology | July 6, 2021 | Volume: 61 | Issue: 6 | Pages: 687-697

10.1111/ijd.15753 | PMID 34227108 Get It

AbstractBackgroundComprehensive treatment recommendations for Merkel cell carcinoma are complex. We aimed to systematically review the published data on recurrence and mortality rates associated with various treatment approaches for Merkel cell carcinoma.MethodsSearch of MEDLINE, Embase, Web of Science, and Scopus from inception to August 2015. Studies were included that reported comparative survival and recurrence data for two or more treatment modalities. Two reviewers independently reviewed and abstracted recurrence and mortality rates. Event rates for individual treatment arms in each study were pooled and meta‐analyzed across studies using a random‐effects model.ResultsFifty‐two retrospective studies met inclusion criteria, revealing a total of 1,804 patients with primary Merkel cell carcinoma with data available for analyses. The recurrence rate was higher for surgery alone (55.0%) versus a combination of surgery and radiotherapy (39.0%) (odds ratio, 2.089; 95% CI, 1.374–3.177; P < 0.001). Combination therapy including surgery, radiotherapy, and chemotherapy had a higher mortality rate (44.6%) than did combined surgery and radiotherapy (23.2%) (odds ratio, 2.688; 95% CI, 1.196–6.037; P = 0.02).ConclusionsThe treatment of Merkel cell carcinoma with surgery plus adjuvant radiotherapy may produce lower recurrence rates.
Copy Number Variation in Parkinson's Disease: An Update from Sub‐Saharan Africa
Müller-Nedebock, Amica Corda , Fawale, Bimbo , Westhuizen, Francois H. van der , Ross, Owen A. , Bardien, Soraya , Müller-Nedebock, Amica C , Ross, Owen A , Bardien, Soraya , Komolafe, Morenikeji Adeyoyin , Carr, Jonathan

Mayo Clinic

Movement Disorders | July 6, 2021 | Volume: 36 | Issue: 10 | Pages: 2442-2444

10.1002/mds.28710 | PMID 34228376 Get It

Increased short‐term and long‐term mortality in community‐ and hospital‐acquired hypernatraemia and in patients with delayed serum sodium correction
Thongprayoon, Charat , Cheungpasitporn, Wisit , Petnak, Tananchai , Miao, Jing , Qian, Qi , Cheungpasitporn, Wisit , Petnak, Tananchai , Thongprayoon, Charat , Miao, Jing

Mayo Clinic

International Journal of Clinical Practice | July 6, 2021 | Volume: 75 | Issue: 10 | Pages: No page available

10.1111/ijcp.14590 | PMID 34227208 Get It

Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma
Desai, Sanjal H. , Wiseman, Gregory A., Desai, Sanjal , Wiseman, Gregory, Moustafa, Muhamad Alhaj , Witzig, Thomas E.

Mayo Clinic

The Oncologist | July 6, 2021 | Volume: 26 | Issue: 11 | Pages: e2079-e2081

10.1002/onco.13895 | PMID 34227176 Get It

AbstractPrimary gastrointestinal follicular lymphoma (PGIFL) is characterized by localized involvement of the gastrointestinal (GI) tract. PGIFL usually runs an indolent course. External beam radiation therapy is curative in a substantial proportion of localized follicular lymphomas, but GI toxicities may discourage its use in PGIFL. Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti-CD20 monoclonal antibody linked to chelator tiuxetan and radioisotope. RIT delivers confined high-intensity radiation with short path length specifically targeting lymphoma cells and sparing normal tissue. In this case series report, we included six cases of PGIFL treated with RIT. All patients had low-risk, localized, and nonbulky disease. All patients responded completely and were relapse-free for the duration of follow-up. Hematologic toxicities were seen, but none were serious. RIT is a potentially curative treatment option in PGIFL with a tolerable toxicity profile.
Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer
Milin‐Lazović, Jelena , Madzarevic, Petar , Rajović, Nina , Milic, Nikola , Pavlović, Sonja , Veljković, Nevena , Milić, Nataša , Radenković, Dejan , Veljkovic, Nevena , Milic, N , Rajovic, Nina , Djordjevic, Vladimir R.

Mayo Clinic

Cancers | July 6, 2021 | Volume: 13 | Issue: 14 | Pages: 3378

10.3390/cancers13143378 | PMID 34298594 Get It

Introduction: The analysis of cell-free DNA (cfDNA) for genetic abnormalities is a promising new approach for the diagnosis and prognosis of pancreatic cancer patients. Insights into the molecular characteristics of pancreatic cancer may provide valuable information, leading to its earlier detection and the development of targeted therapies. Material and Methods: We conducted a systematic review and a meta-analysis of studies that reported cfDNA in pancreatic ductal adenocarcinoma (PDAC). The studies were considered eligible if they included patients with PDAC, if they had blood tests for cfDNA/ctDNA, and if they analyzed the prognostic value of cfDNA/ctDNA for patients’ survival. The studies published before 22 October 2020 were identified through the PubMED, EMBASE, Web of Science and Cochrane Library databases. The assessed outcomes were the overall (OS) and progression-free survival (PFS), expressed as the log hazard ratio (HR) and standard error (SE). The summary of the HR effect size was estimated by pooling the individual trial results using the Review Manager, version 5.3, Cochrane Collaboration. The heterogeneity was assessed using the Cochran Q test and I2 statistic. Results: In total, 48 studies were included in the qualitative review, while 44 were assessed in the quantitative synthesis, with the total number of patients included being 3524. Overall negative impacts of cfDNA and KRAS mutations on OS and PFS in PDAC (HR = 2.42, 95% CI: 1.95–2.99 and HR = 2.46, 95% CI: 2.01–3.00, respectively) were found. The subgroup analysis of the locally advanced and metastatic disease presented similar results (HR = 2.51, 95% CI: 1.90–3.31). In the studies assessing the pre-treatment presence of KRAS, there was a moderate to high degree of heterogeneity (I2 = 87% and I2 = 48%, for OS and PFS, respectively), which was remarkably decreased in the analysis of the studies measuring post-treatment KRAS (I2 = 24% and I2 = 0%, for OS and PFS, respectively). The patients who were KRAS positive before but KRAS negative after treatment had a better prognosis than the persistently KRAS-positive patients (HR = 5.30, 95% CI: 1.02–27.63). Conclusion: The assessment of KRAS mutation by liquid biopsy can be considered as an additional tool for the estimation of the disease course and outcome in PDAC patients.
Chemoradiation and Local Excision Versus Total Mesorectal Excision for T2N0 Rectal Cancer
Lynn, Patricio B. , Valk, Maxime J.M. van der, Claassen, Y.H.M. , Shi, Qian , Widmar, Maria , Bastiaannet, E, Velde, Cornelis J.�H. van de , García‐Aguilar, Julio , Shi, Qian

Mayo Clinic

Annals of Surgery | July 6, 2021 | Volume: 277 | Issue: 1 | Pages: e96-e102

10.1097/sla.0000000000005052 | PMID 34225302 Get It

Objective: Compare oncological long-term and short-term outcomes between patients with distal cT2NO rectal cancer treated with chemoradio-therapy and local excision (CRT + LE) and patients treated with total mesorectal excision (TME). Summary Background Data: Previous studies showed that CRT + LE is equivalent to TME in local tumor control and survival for T2N0 rectal cancer. Methods: Seventy-nine patients with cT2N0 rectal adenocarcinoma treated with CRT + LE in the ACOSOG Z6041 trial were compared to a cohort of 79 patients with pT2N0 tumors treated with upfront TME in the Dutch TME trial. Survival, short-term outcomes, and health-related quality of life (HRQOL) were compared between groups. Results: Three patients (4%) in the CRT + LE group required abdominoperineal resection, compared with 31 (40%) in the TME group. Forty TME patients (51%) required a permanent stoma. CRT-related toxicity occurred in 43% of the CRT + LE patients; however, TME patients had a higher rate of complications requiring reoperation (1 vs 9%; P = 0.03). Five-year disease-free survival {88.2% [confidence interval (CI), 77.7%–93.9%] vs 88.3% [CI, 78.7%–93.7%]; P = 0.88} and overall survival [90.3% (CI, 80.8%–95.3%) vs 88.4% (CI, 78.9%–93.8%); P = 0.82] were similar in the 2 groups. Compared to baseline, overall HRQOL decreased in the CRT + LE group and improved in the TME group. In both groups, patients with sphincter preservation had worse HRQOL scores 1 year after surgery. Conclusions: In patients who underwent CRT + LE, oncological outcomes were similar to those of patients who underwent TME, with fewer complications requiring reoperation but significant CRT toxicity. Although overall HRQOL decreased in the CRT + LE group and improved in TME patients, when considering anorectal function, results were worse in both groups.
Teaching NeuroImages: Neuroimaging Findings in Inosine Triphosphate Pyrophosphohydrolase Deficiency
Boyer, Suzanne, Bierau, Jörgen , Wortmann, Saskia B. , Muthusamy, Karthik , Patterson, Marc, Wortmann, Saskia, Boyer, Suzanne , Patterson, Marc C. , Morava, Éva

Mayo Clinic

Neurology | July 6, 2021 | Volume: 97 | Issue: 1 | Pages: No page available

10.1212/wnl.0000000000011719 | PMID 33593863 Get It